Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06463977 · ClinicalTrials.gov registry record
Using Surveys to Examine the Association of Exposure to ML Mortality Risk Predictions With Medical Oncologists' Prognostic Accuracy and Decision-making
A clinical trial, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- 52
- Enrollment target
NCT06463977 is a clinical trial that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 52 participants.
The verdict
NCT06463977 has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- 52 participants
- Enrollment target
Study Summary
Nearly half of cancer patients in the US will receive care that is inconsistent with their wishes prior to death. Early advanced care planning (ACP) and palliative care improve goal-concordant care and symptoms and reduce unnecessary utilization. A promising strategy to increase ACP and palliative care is to identify patients at risk of mortality earlier in the disease course in order to target these services. Machine learning (ML) algorithms have been used in various industries, including medicine, to accurately predict risk of adverse outcomes and direct earlier resources. "Human-machine collaborations" - systems that leverage both ML and human intuition - have been shown to improve predictions and decision-making in various situations, but it is not known whether human-machine collaborations can improve prognostic accuracy and lead to greater and earlier ACP and palliative care. In this study, we contacted a national sample of medical oncologists and invited them complete a vignette-based survey. Our goal was to examine the association of exposure to ML mortality risk predictions with clinicians' prognostic accuracy and decision-making. We presented a series of six vignettes describing three clinical scenarios specific to a patient with advanced non-small cell lung cancer (aNSCLC) that differ by age, gender, performance status, smoking history, extent of disease, symptoms and molecular status. We will use these vignette-based surveys to examine the association of exposure to ML mortality risk predictions with medical oncologists' prognostic accuracy and decision-making.
Interventions
- OTHER Survey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2023-03-13 |
| Est. Completion | 2023-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06463977
The ClinicalTrials.gov registry entry for NCT06463977 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Survey is the first listed.
NCT06463977 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06463977 about?
NCT06463977 is a clinical study titled "Using Surveys to Examine the Association of Exposure to ML Mortality Risk Predictions With Medical Oncologists' Prognostic Accuracy and Decision-making". Nearly half of cancer patients in the US will receive care that is inconsistent with their wishes prior to death. Early advanced care planning (ACP) and palliative care improve goal-concordant care and symptoms and reduce unnecessary utilization. A promising strategy to increase ACP and palliative c...
What is the current status of trial NCT06463977?
This trial is currently completed. The enrollment target is 52 participants. The study started on 2023-03-13. Estimated completion is 2023-12-31.
What interventions are being tested in trial NCT06463977?
The interventions under investigation include: Survey (OTHER).
Who is sponsoring clinical trial NCT06463977?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.